Summary:
In healthy Chinese adults (n=32), once-daily oral semaglutide escalated from 3 mg to 14 mg over 12 weeks demonstrated dose-dependent exposure (AUC, Cmax) comparable to global populations, with significant reductions in body weight (P=0.0001) and fasting glucose (P=0.0011) compared to matching placebo, with primarily GI adverse events (nausea, decreased appetite), no severe hypoglycemia or serious AEs.
| PICO | Description |
|---|---|
| Population | Healthy Chinese adults (n=32), randomized to oral semaglutide or placebo. |
| Intervention | Once-daily oral semaglutide with dose escalation 3 mg → 7 mg → 14 mg over 12 weeks. |
| Comparison | Matching placebo under identical conditions (fasting, 30-min post-dose fasting). |
| Outcome | Dose-dependent exposure. Significant weight and glucose reductions. GI AEs consistent with class. |
Clinical Context
Oral semaglutide uses SNAC technology for GI absorption. Asian populations may have different PK profiles requiring bridging studies.
Clinical Pearls
1. Pharmacokinetics Confirm Global Dosing Applicability: Exposure comparable to global trials, validating same dose escalation.
2. Effects Evident Even in Healthy Volunteers: Significant weight and glucose reductions in normoglycemic subjects.
3. GI Tolerability Profile Consistent: Nausea, decreased appetite mirror global experience.
4. No Hypoglycemia Without Diabetes Background: Confirms glucose-dependent insulin secretion.
Practical Application
Prescribe oral semaglutide in Chinese patients using standard global protocols. Take on empty stomach with ≤120 mL water, wait 30 minutes before eating.
Study Limitations
Small sample size (n=32). Healthy volunteer population. 12-week duration.
Bottom Line
Oral semaglutide demonstrates comparable PK in Chinese adults, supporting standard dosing protocols for Chinese patients.
Source: Xie P, et al. “A Phase 1 Trial Investigating Oral Semaglutide in Healthy Chinese Subjects.” Diabetes, Obesity and Metabolism. Read article